Taken together, current data suggest that blocking IL-33/ST2 signal may reduce the degree of inflammation and symptoms in EoE and GERD; however, whether targeting the IL-33/ST2 axis can affect the development of EoE and GERD is still an uncertain issue, and more studies are needed. Here, IL33 is linked to gastroesophageal reflux disease.